| Followers | 73 |
| Posts | 3426 |
| Boards Moderated | 1 |
| Alias Born | 04/28/2004 |
Wednesday, April 10, 2013 1:20:49 PM
ONXX:
I agree. I was commenting more so from the market perception side.
I think the palbociclib data to date have been strong enough that breakthrough therapy designation is not altogether meaningful.
As a goofy aside, I think palbociclib is going to be an oft-misspelled name among investors. The allure of pablociclib is too high
Yes, but only marginally; however, many investors probably think the breakthrough therapy designation is a very big deal.
I agree. I was commenting more so from the market perception side.
I think the palbociclib data to date have been strong enough that breakthrough therapy designation is not altogether meaningful.
As a goofy aside, I think palbociclib is going to be an oft-misspelled name among investors. The allure of pablociclib is too high
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
